Many small fruits carry a host of benefits for the human body with blueberries leading the pack in healthy qualities. Often termed the “superfruit,” they are packed with disease-fighting antioxidants; so much so that scientists at the U.S. Department of Agriculture ranked them at the top of the list in antioxidant activity when compared to 40 other fresh fruits and vegetables. Further, recent research at Texas Women’s University has determined that blueberries might ward off the development of fat cells, which could be used to combat obesity.

ChromaDex, Inc., an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food & beverage, cosmetic and pharmaceutical industries, has developed a way to harness the powers of the little blue fruit by amplifying the critical components into a single product called pTeroPure™ pterostilbene. This unique, patent-pending product is a 99% pure form of trans-pterostilbene, the vital portion of the blueberry (as well as other small fruits and bark and heartwood of some trees), which has shown promising health benefits and is gathering steam within the nutraceutical industry. ChromaDex’s product is manufactured through green chemistry and packs a true wallop; providing the pterostilbene equivalent of more than 300 pounds of blueberries in a single dose.

In comparison, pterostilbene is similar in composition to resveratrol, the compound that has been widely-publicized for giving red wine its healthy property. The twist is that while less-known at the moment, pterostilbene possesses a greater potential benefit due to a half-life in the body that is more than four times that of resveratrol.

To bolster validity of the product, ChromaDex has worked with leading institutions, including the U.S. Department of Agriculture, to research the effects of pterostilbene. Their studies showed that pterostilbene may positively impact clinical conditions such as cardiovascular diseases and cognitive decline as well as possibly serve as an indication for diabetes, blood pressure, cancer, oxidative stress and anti-ageing. What these facts do is significantly increase the marketability of pTeroPure pterostilbene to beyond the breadth of simply the nutraceutical industry that was once the initial focus.

ChromaDex is not sitting idly by letting the market come to them. They are actively advertising and marketing to educate both the industry and the general population as to the magnitude of benefits of pTeroPure™. There has been a wide acceptance and generation of demand already even with the product only having been launched less than one year ago. To date, it is employed in fourteen finished products with an additional twelve slated to hit the market this summer.

Recently, after examination and analysis of the health ingredients market, Frost & Sullivan recognized ChromaDex with the 2010 North American Frost & Sullivan Award for “Most Promising Ingredient of the Year” for the unique pTeroPure pterostilbene ingredient.

ChromaDex stands out as a bulletin board-listed company as it does not carry with it the purely speculative nature that so many companies do on the exchange. It is generating revenue, has cash on hand and has a commercially viable product with exponential growth potential. Revenue for 2010 tallied in excess of $7 million, which should increase substantially as pTeroPure™ pterostilbene continues to garner industry attention and additional partnering and co-branding relationships are nurtured.

More information on ChromaDex can be found on the Company’s website at